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Abstract: Although medical treatment of COPD has advanced, nonadherence to medication 
regimens poses a signiﬁ  cant barrier to optimal management. Underuse, overuse, and improper use 
continue to be the most common causes of poor adherence to therapy. An average of 40%–60% 
of patients with COPD adheres to the prescribed regimen and only 1 out of 10 patients with a 
metered dose inhaler performs all essential steps correctly. Adherence to therapy is multifactorial 
and involves both the patient and the primary care provider. The effect of patient instruction 
on inhaler adherence and rescue medication utilization in patients with COPD does not seem 
to parallel the good results reported in patients with asthma. While use of a combined inhaler 
may facilitate adherence to medications and improve efﬁ  cacy, pharmacoeconomic factors may 
inﬂ  uence patient’s selection of both the device and the regimen. Patient’s health beliefs, expe-
riences, and behaviors play a signiﬁ  cant role in adherence to pharmacological therapy. This 
manuscript reviews important aspects associated with medication adherence in patients with 
COPD and identiﬁ  es some predictors of poor adherence.
Keywords: adherence, chronic obstructive pulmonary disease, compliance, inhalers, inhalation 
technique, patient preference, quality of life
Introduction to management issues in COPD
According to the World Health Organization (WHO) estimates, currently 210 million 
people have COPD and 3 million people died of COPD in 2005. The WHO predicts 
that COPD will become the fourth leading cause of death worldwide by 2030 (COPD 
2007). The burden of COPD assessed by disability-adjusted life years (DALYs) ranks 
10th worldwide (WHO 2008). Total deaths from COPD are projected to increase by 
more than 30% in the next 10 years unless urgent preventive measures are in place 
(COPD 2007).
Although COPD cannot be cured, optimal management provides symptom control, 
slows progression of the disease, and may improve the quality of life (Kaplan and Ries 
2005; Rodriguez-Roisin 2005). Management of COPD becomes suboptimal when 
physicians fail to prescribe appropriate therapies, due to poor adherence to evidence-
based guidelines and underdiagnosis (Snider 1985; Foster et al 2007), or when patients 
fail to adhere to prescribed treatment regimens. There are a limited number of studies 
on the physician knowledge and practice patterns for individuals with COPD that may 
result in suboptimal management and adversely affect patient outcomes (Ramsey 2000; 
George et al 2005; Foster et al 2007; Sestini et al 2007).
Adherence is deﬁ  ned as “the extent to which a person’s behavior (in terms of 
taking medications, following diets, or executing lifestyle changes) coincides with 
medical or health advice” (Haynes et al 1979). Adherence to medication regimens 
is often suboptimal when patients are on long-term pharmacotherapy using repeat 
prescriptions. A study published by the WHO estimated 50% adherence or less for 
patients on long-term pharmacotherapy (WHO 2003).International Journal of COPD 2008:3(3) 372
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Adhering to inhaled medications is of paramount 
importance in the management of patients with COPD in 
both clinical and ambulatory settings. These pharmacologic 
agents include bronchodilators and corticosteroids used in a 
variety of aerosol devices that include small volume nebuliz-
ers (SVNs), pressurized metered-dose inhalers (pMDIs), and 
dry powder inhalers (DPIs). Selection of the medication and 
the device typically depends on the efﬁ  cacy of the different 
inhaled medications and the devices. However, this selec-
tion is often limited by the availability of a match between 
the medication prescribed and the aerosol device. While it 
is desirable that the medications prescribed to a patient are 
delivered through the same or similar devices, adherence to 
the right medication – device combination may be inﬂ  uenced 
by commercial availability. The medication – device avail-
ability problem will be compounded by the phasing-out of 
CFC-propelled pMDIs at the end of 2009 as proposed by the 
Federal register ruling (FDA 2007). Replacement of CFC-
propelled pMDIs by hydroﬂ  uoroalkane (HFA)-propelled 
pMDIs has been more difﬁ  cult than expected since it has 
resulted in a redesign of the entire pMDI metering-valve 
system at a higher cost than simply replacing the propellant. 
This transitioning will initially restrict the list of available 
agents and could have considerable ﬁ  nancial implications in 
the routine management of patients with COPD (Rau 2005; 
Smyth 2005).
Medication regimens for patients with COPD are par-
ticularly vulnerable to adherence problems because of the 
chronic nature of the disease, the use of multiple medica-
tions or polypharmacy, and the periods of symptom remis-
sion. Patients with COPD are often prescribed aerosolized 
medications to use from 2 to 6 times daily plus concurrent 
therapy for other comorbidities that may include diabetes, 
hypertension, and coronary artery disease (Krigsman et al 
2007a; Steinman et al 2006).
Despite the efforts of the global initiative for chronic 
obstructive lung disease (GOLD) to provide clinicians with 
the best therapeutic guidance, adherence to pharmacologic 
therapy among patients with COPD has been historically 
poor (Windsor et al 1980; Kaplan et al 1990; Dolce et al 
1991; George et al 2005; Krigsman et al 2007b, c). Patients 
with COPD display signiﬁ  cantly lower adherence to treat-
ment than asthmatic patients (James et al 1985; Cochrane 
1992; Haupt et al 2008). Several studies have reported that 
an average of 60% of patients with COPD do not adhere to 
prescribed therapy (Chryssidis et al 1981; Taylor et al 1984; 
Dompeling et al 1992; Bosley et al 1994; Krigsman et al 
2007b, c; Haupt et al 2008) and that up to 85% of patients 
use their inhaler ineffectively (Crompton 1990; Thompson 
et al 1994; Van Beerendonk et al 1998; van der Palen et al 
1995, 1998; Hesselink et al 2001; Serra-Batlles et al 2002). 
British and Swedish studies indicate that 10%–20% of repeat 
prescriptions never reach a pharmacy (Rashid 1982; Nilsson 
et al 1995).
Adherence to therapy in COPD is complex. Patients with 
COPD require adequate education on the disease process, 
comorbidities, and also on the use of different medications 
and devices (Chryssidis et al 1981; Dolce et al 1991). They 
often need to make important behavioral and lifestyle changes 
such as starting a smoking cessation program, adhering to 
an exercise program, and wearing oxygen.
Several methods are used to measure adherence: reﬁ  ll 
adherence based on pharmacy records of dispensed pre-
scription or manual recording of collected prescriptions, 
and self-reports of compliance using medication adherence 
report scales (MARS) (George et al 2005). Although adher-
ence should ideally be measured upon ingestion or admin-
istration of the medication, this is not practical for large 
groups. Most studies rely on a mixture of reﬁ  ll adherence 
and self-report. Since the most commonly used method to 
measure is the self-report (Farmer 1999) this review focuses 
only on this technique.
Numerous factors predispose patients with COPD to 
poor adherence. Recognition of the type of nonadherence 
in patients with COPD must be the ﬁ  rst step in this compli-
cated process of improving adherence. Prescription of an 
inhaled medication requires knowledge of different groups 
of medications and the potential clinical efﬁ  cacy of combi-
nations. It also requires being familiar with several aerosol 
delivery devices. Newer medications and devices improve 
clinical outcomes and ease of use but typically mean a higher 
out-of-pocket expense for patients. Patient’s perceptions of 
their illness, their understanding of the treatment, and their 
relationship with the primary care provider are critical to 
adherence to therapy. It is the aim of this manuscript is to 
review some of these important aspects affecting adherence 
to medication and to identify some predictors of poor adher-
ence in patients with COPD.
Underuse, overuse, 
and improper use
There are three classic types of nonadherence to therapy: 
underuse, overuse, and improper use. Underuse is deﬁ  ned 
as a reduction of the apparent daily use versus a standard 
dose of a medication that is indicated for the treatment or 
prevention of a disease or condition (Lipton et al 1992; International Journal of COPD 2008:3(3) 373
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Harrow et al 1997). Improper use or inappropriate use is 
conﬁ  rmed by determining whether a drug is ineffective, not 
indicated, or if there is unnecessary duplication of therapy 
(Steinman et al 2006).
Although these three factors have been well deﬁ  ned 
in the literature, there is limited evidence that links spe-
ciﬁ  c factors to each form of nonadherence in patients 
with COPD. The most common type of nonadherence 
in patients with COPD is underuse (Harrow et al 1997; 
George et al 2005). By contrast, improper use is the most 
frequent type of nonadherence in patients older than 65 
years with polypharmacy (taking 2 or more medications) 
(Steinman et al 2006). Factors with tendency for associa-
tion with unnecessary drug use include white race, income 
 US$30,000/year, more than 6.8 (±2) of prescription 
medications, and lack of patient’s health belief (Rossi et al 
2007). In older adults, higher levels of independence and 
self-reliance have been associated with lower adherence 
to a medication regimen (Insel et al 2006). The two most 
common reasons for a medication to be considered inap-
propriate are lack of effectiveness and lack of indication 
(Hajjar et al 2005; Steinman et al 2006; Rossi et al 2007). 
Inhaled medications are not on the top 5 medications that 
are inappropriately used in patients older than 65 years 
(Hajjar et al 2005; Rossi et al 2007).
In patients with COPD, underuse is followed in frequency 
by overuse and improper use of the medication delivering 
device. Underuse could be sporadic or systematic. From 
forgetting an occasional dose to changing dosing schedule, 
patients with underuse are at a higher risk for adherence-
related morbidity. A recent evaluation of the use of ICS in 
primary care patients revealed that up to 30% of the patients 
did not have a clear indication for this medication (Lucas et al 
2008). Although improper use and underuse often coexist 
in the same patient, improper use may not correlate with 
underuse (Steinman et al 2006).
There is evidence of overuse of short-acting beta agonists 
in patients with asthma (Lynd et al 2002), but little is known 
about the real incidence of overuse in patients with COPD. 
During respiratory distress, approximately half of the patients 
report using more than the prescribed amount of medications 
(Dolce et al 1991; Bosley et al 1994).
Clinical efﬁ  cacy of major classes 
of medications and combinations
Determination of clinical efﬁ  cacy involves evaluation of 
outcomes such as lung function, rate of exacerbations, 
and mortality. However, these outcome parameters need 
to be a reﬂ  ection of the clinical efﬁ  cacy perceived by the 
patient. A combination of objective and subjective clinical 
efﬁ  cacy is a critical determinant of adherence to therapy. 
Inhaled corticosteroids (ICS), long-acting β2-agonists 
(LABAs), and anticholinergics have been recommended 
for the treatment of COPD. LABAs are recommended by 
GOLD (GOLD 2007) when patients continue to experience 
problems on short-acting bronchodilators (SABAs). The 
most obvious beneﬁ  t of combination therapy is in terms 
of patient convenience that may lead to greater treatment 
adherence.
Lung function
Current evidence indicates that there is statistically signiﬁ  cant 
difference in FEV1 and in health status measurements in 
favor of LABAs (Appleton et al 2006) and ICS (Yang et al 
2007). Several randomized controlled trials have found that 
a LABA – ICS combination therapy is associated with a 
signiﬁ  cant increase over the baseline FEV1 when compared 
with the groups receiving placebo, LABA alone, or ICS 
alone (Calverley et al 2007; Nannini et al 2007a). Addition 
of tiotropium to the LABA – ICS combination signiﬁ  cantly 
improves lung function (Aaron et al 2007). The combina-
tion of ipratropium bromide and albuterol in patients with 
COPD results in signiﬁ  cant improvement in peak FEV1 
compared with albuterol or ipratropium alone (Gross et al 
1998). Tashkin et al (2007) reported no signiﬁ  cant difference 
in lung function measured by FEV1 in a group of patients 
with COPD randomized to SVN, pMDI, and concomitant 
treatment involving SVN (morning and night) plus pMDI 
(afternoon and evening) using a combination of albuterol 
and ipratropium bromide.
Rate of exacerbations, hospitalizations, 
and mortality
Using LABA – ICS is associated with a signiﬁ  cant reduction 
in the rate of exacerbation, admission rates, and mortality 
(Aaron et al 2007; Calverley et al 2007; Nannini et al 2007b, 
7c). Combination therapy may reduce 1 exacerbation of 
COPD every 2–4 years (Calverley et al 2007). Patients with 
COPD at any stage may perceive the lower health resource 
utilization as a motivator to adhere more rigorously to medi-
cations. However, this correlation has not been determined. 
Trials of short-acting anticholinergic and SABA combina-
tions have shown a signiﬁ  cant reduction in exacerbations 
compared with monotherapy, but no difference in mortality 
(Sin et al 2003).International Journal of COPD 2008:3(3) 374
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Use of rescue medication
The use of rescue medications during COPD exacerbations 
may seem to be the most feasible explanation for overuse. 
During an exacerbation, an average of 1 additional puff 
during the day and half a puff during the night is seen 
two weeks prior and after an exacerbation regardless of 
COPD stage (Calverley et al 2005). However, changes in 
rescue medication intake poorly correlate with exacerba-
tions (Calverley et al 2005). The use of LABA – ICS 
has been associated with a signiﬁ  cant reduction in mean 
puffs per day of SABA (Mahler et al 2002; Hanania et al 
2003), signiﬁ  cant increases in the percentage of nights 
with no awakenings requiring SABA versus placebo, 
and a signiﬁ  cant difference in median percentage of days 
without use of relief medication (Calverley et al 2003a, b; 
Szafranski et al 2003).
Safety and tolerability of major 
classes of medications and 
combinations
Adverse events to medications are reported by 90% of the 
patients with COPD (Calverley et al 2007). The presence 
of serious side effects negatively affects adherence. An 
increase in the risk of pneumonia in patients with COPD 
using a combination of ICS and LABA has been reported 
in several studies (Calverley et al 2007; Nannini et al 
2007b). The most frequently reported adverse event was 
an exacerbation of COPD. Although there is no signiﬁ  cant 
difference in the occurrence of overall reported adverse 
events between LABA – ICS and placebo, pneumonia, 
candidiasis, nasopharyngitis, hoarseness, and upper respi-
ratory tract infections (URTI) occurred more frequently 
when treated with a LABA – ICS combination (Table 1) 
(Nannini et al 2007a).
Adherence to individual 
medications and combinations
Type of medication
Patients with COPD have the lowest adherence to a regimen 
that included inhaled anticholinergic agents followed in order 
by the inhaled sympathomimetics, theophylline, corticoste-
roids, and antibiotics (Dolce et al 1991) (Figure 1).
The ability to produce quick relief of symptoms or the 
safety proﬁ  les could explain class differences. It has been 
suggested that compliance to corticosteroids should be 
lower than to bronchodilators, because of the lack of direct 
symptom-relieving effect of the corticosteroids. However, 
patients may adhere to regimens that include oral corti-
costeroids and antibiotics more frequently because these 
medications are typically prescribed for short periods of 
time. Since they are prescribed to deal with acute symptoms, 
the patients’ perception is that these medications are more 
urgent and necessary.
Complexity of medication regimens
It has been previously reported that overall, the average 
number of time-contingent and as needed (P.R.N.) medica-
tions per patient may be as high as 6.26 (range, 1–16) (Dolce 
et al 1991). Up to 77% of patients with COPD may receive 
2 or more oral-contingent medications (Dolce et al 1991). 
One-third typically receive 2 or more inhaled time-contin-
gent medications, 45% receive 1 inhaled time-contingent 
medication, and 23% receive no inhaled time-contingent 
medications (Dolce et al 1991). The average of prescribed 
oral time-contingent and inhaled time-contingent medica-
tions are 3.53 and 1.17, respectively. Thirty percent of 
patients with COPD are prescribed oral P.R.N. medications 
and 17% had inhaled P.R.N. medications (Dolce et al 1991). 
Many of these medications have different dosing schedules. 
Thus, it is quite common for patients to be prescribed a 
combination of 5–8 oral and inhaled medications, with 
many medications requiring different dosing patterns.
Use of ipratropium bromide and albuterol in one inhaler 
is associated with a signiﬁ  cantly lower risk of an emergency 
department visit or hospitalization, lower mean monthly 
health charges, shorter hospital stays, and greater likeli-
hood of compliance than if used in two separate inhalers 
(Chrischilles et al 2002).
Selection of the aerosol delivery 
device
All aerosol delivery devices have relative advantages and 
disadvantages, as well as a potential to affect outcomes. 
The marketing of a myriad of aerosol delivery devices has 
resulted in a confusing number of choices for clinicians and 
Table 1 Most common adverse effects with combination therapy
Adverse   Nr of   Nr of   OR; 95% CI
effect studies  patients
Pneumonia  7  5229  OR 1.80; 95% CI 1.48–2.18
Candidiasis  6  1958  OR 5.73; 95% CI 3.07–10.67
Hoarseness  2  585  OR 8.79; 95% CI 1.11–69.62
Nasopharyngitis  2  3535  OR 1.28; 95% CI 1.05–1.56
URTI  5  4963  OR 1.23; 95% CI 1.04–1.47
Abbreviations: CI, conﬁ  dence interval; OR, odds ratio; URTI, upper respiratory 
tract infections.International Journal of COPD 2008:3(3) 375
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patients. Although the fundamental principle of prescribing 
is based on the use of the most clinical and cost-effective 
medication and device, choices may become inﬂ  uenced by 
factors that are not clinically relevant or evidence-based. 
The ability of the patient to use the prescribed device affects 
adherence to treatment.
Clinical efﬁ  cacy
The overall conclusion of numerous studies demonstrates 
that there is no evidence to support clinically important 
differences between aerosol devices. A systematic review 
(Dolovich et al 2005) identiﬁ  ed 394 randomized controlled 
trials (RCTs) assessing inhaled corticosteroid, β2-agonist, and 
anticholinergic agents that were delivered by pMDI, pMDI 
with spacer/holding chamber, nebulizer, or DPI. None of the 
pooled meta-analyses found a signiﬁ  cant difference between 
devices in any efﬁ  cacy outcome of patients with asthma and 
COPD in the outpatient and hospital acute care settings. A 
recent clinical trial (Tashkin et al 2007) reported no appre-
ciable changes from baseline or pair wise differences between 
SVN and pMDI treatment arms at weeks 6 or 12 in peak ﬂ  ow 
measurements and symptom scores of patients with COPD.
In all the pooled meta-analyses, each of the delivery 
devices has provided similar outcomes in patients using the 
correct technique for inhalation. However, clinical beneﬁ  t 
also depends on the ability of the patients to use the device 
and on their adherence. Real-life observational studies that 
evaluated patient inhalation techniques have shown frequent 
improper use of pMDIs and DPIs that may result in signiﬁ  cant 
clinical differences between devices.
Patient acceptability and preference
Elderly patients with COPD show a preference for the SVN 
with regard to effectiveness and in favor of the pMDI with 
regard to acceptability (Balzano et al 2000). SVN treatment is 
often prescribed to patients who prefer SVNs or demonstrate 
poor coordination with either a pMDI or DPI. Because SVNs 
are not as portable as pMDIs or DPIs, ambulatory patients 
ﬁ  nd pMDIs and DPIs more convenient for use when they 
are away from home.
Inhalers and dosing technique
Although patients may adhere to the dosing schedule, they 
may use the inhaler improperly (McFadden 1986). Inhaler 
speciﬁ  c design features also contribute signiﬁ  cantly to 
the patient’s adherence to treatment (Brown et al 1992; 
Woodman et al 1993; van der Palen et al 1994). Patient 
technique is a process that encompasses an individual’s 
previous experiences, education, abilities, and the teaching 
received on the speciﬁ  c device. These factors may interact 
to various degrees with the different types of inhaler devices 
to inﬂ  uence eventual technique and adherence. The typi-
cal method to evaluate inhaler technique is by assigning a 
score on the number of steps performed correctly out of 
the total number of possible steps. An evaluation of inhaler 
use in 316 patients suffering from asthma or COPD found 
that 89% of the patients made at least one mistake in the 
inhalation technique (van Beerendonk et al 1998). The most 
common skill error was “not continuing to inhale slowly 
after actuation of the inhaler” (69.6%). The nonskill item 
most patients had difﬁ  culties with was “exhaling before 
the inhalation” (65.8%). Patients who used a pMDI made 
signiﬁ  cantly fewer nonskill mistakes than patients using 
a DPI (van Beerendonk et al 1998). A systematic review 
(Brocklebank and Ram 2001) using the outcome of “ideal” 
inhaler technique showed that the percentage of patients 
with all steps correct was 43% for pMDI alone, 55% for 
pMDI + spacer, and 59% for DPI. There was statistical 
Figure 1 Percentage of nonadherence to prescribed medication category.
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difference between pMDI alone and DPI or pMDI + spacer, 
but whether this is clinically signiﬁ  cant is difﬁ  cult to judge, 
particularly if cost efﬁ  cacy is considered. The data sup-
port the conclusion of many reports that pMDI devices are 
poorly used.
When the pMDI is used, more than 50% of subjects may 
perform  5 out of 9 steps correctly and only about 11% 
of the subjects could perform all steps correctly (Luk et al 
2006) (see Table 2).
The most frequent problem is failure to coordinate actua-
tion with inhalation and to hold their breath after inhalation. 
When patients are asked simple questions to establish if they 
have a basic understanding of their nebulized medication (eg, 
do you know what medications you use? how often? do you 
know if the medication you take has a bronchodilatory or 
anti-inﬂ  ammatory effect?), 52% of patients are not able to 
answer these questions correctly; although 91% believe that 
they do understand the treatment they were prescribed. Of 
those who are unable to answer correctly, 60% are nonadher-
ent (Bosley et al 1996). To complicate matters, primary care 
physicians are not familiar with relevant features of currently 
available inhalers (Sestini et al 2007).
Patient preference – ease of use
In a recent comparison of the Diskus® inhaler (DK) and the 
Handihaler® (HH) regarding preference and ease of use, 
although there was no difference in the number of instructions 
needed for both inhalers, more patients preferred the DK. 
The most important general items for patients were hygiene 
and a clear instruction leaﬂ  et (van der Palen et al 2007). Of 
the inhaler-speciﬁ  c aspects, more than 90% of patients ﬁ  nd 
ease of use in general, ability to take the medication quickly, 
ease of use during an exacerbation, the feel in the hand, 
and ease of the cap important or very important (Figure 2).
Inhaler resistance is a factor that contributes to suboptimal 
inhalation of medication in patients with COPD. Over the 
years, there has been a trend to increase inhaler resistance. 
Patients have a preference for devices that allow them to 
inhale the medication quickly (van der Palen et al 2007). 
Eight popular DPIs seem to be acceptable with regard to their 
internal resistance, but the trend to increase the resistance 
of inhalers may have reached a critical point with regard to 
acceptability (van der Palen et al 2007).
Patients report overwhelmingly (98% vs 2%) that per-
ceived beneﬁ  ts from using a SVN over a pMDI or DPI (eg, 
improved breathing, greater self-conﬁ  dence, and less need 
to contact health care providers) outweigh perceived disad-
vantages (eg, longer time required for nebulizer treatment 
and cleaning the device) (Barta et al 2002).
Pharmacoeconomics
Pharmacoeconomics has emerged to formalize the decision-
making process for the adoption of new medications and 
devices. In addition, the implementation of clinical practice 
guidelines can be costly (Haycox and Bagust 1999). In the 
US, in 2000, the total annual costs related to COPD were 
in excess of $US32 billion (COPD 2008). In the US, 97% 
of people over 65 years who receive incomplete Medicare 
coverage need supplemental insurance (Roberts 2006). 
Since the Medicare Prescription Drug Improvement and 
Modernization Act of 2003 only went into effect in 2006, its 
impact on suboptimal medication use is still to be determined 
(Maio et al 2005).
Medication-related cost
Although underuse can result in morbidity and health care 
cost, the cost of the medication is believed to be one of the 
most important determinants of underuse (Hanlon et al 2001; 
Stuart 2004; Maio et al 2005). Tiotropium has demonstrated 
the highest expected net beneﬁ  t for ratios of the willingness 
to pay per quality-adjusted life-year (QALY) (Rutten-van 
Mölken et al 2007). The incremental cost per additional QALY 
is lower with tiotropium than salmeterol or ipratropium bro-
mide (Oba 2007). The practice of offering tiotropium bromide 
for patients with COPD-related hospitalizations instead of 
ipratropium bromide is favored (Onukwugha et al 2008). There 
is a potential overall cost saving of 83% after the addition of 
tiotropium to the medical regimen of patients with COPD 
(Lee et al 2006). Fluticasone – salmeterol (FLU – SAL) and 
budesonide – formoterol (BUD – FOR) are the most cost 
effective strategies. However, there is a slight superiority of 
FLU – SAL. Incremental cost-effectiveness of FLU – SAL 
versus SAL was  679.5 (US$1,001) per avoided exacerbation 
and  3.3 (US$4.86) per symptom-free day (Dal et al 2007).
Table 2 Steps for correct use of the inhaler
Steps for correct use of the inhaler
1. Remove  cover
2.  Shake inhaler well
3.  Hold inhaler upright
4. Exhale  gently
5. Place  mouthpiece
6.  Actuate canister once at the beginning of inhalation
7.  Inhale slowly and deeply
8.  Hold breath at least 10 seconds
9.  Breath out slowlyInternational Journal of COPD 2008:3(3) 377
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Device-related cost
Important breakthroughs in biotechnology and nanotech-
nology have resulted in the creation of a myriad of aerosol 
devices that have dramatically improved medication deliv-
ery to patients with respiratory diseases (Dames et al 2007; 
Dhand 2008). However, these advances have come at a 
steep price. It is well known that the costs of both the DPIs 
and SVNs are substantially higher than pMDI devices for 
all classes of medication (Brocklebank and Ram 2001), that 
there is lack of many DPIs in generic forms, and that while 
80% of SVNs and medications are reimbursable by Medi-
care, pMDIs and DPIs are not covered (Rau 2005). Although 
spacers signiﬁ  cantly improve drug delivery, the high cost of 
these simple attachments may be sufﬁ  cient to deter many 
patients from using them. Although routine substitution of 
pMDI therapy for SVN therapy can be accomplished with 
considerable reductions in the hospital setting (Bowton et al 
1992), several authors have reported that no aerosol delivery 
device could be categorically rated as not cost-effective 
(Peters et al 2002).
Patient beliefs, experiences, 
and behaviors
Signiﬁ  cant differences in health beliefs, experiences, and 
behaviors are observed between COPD patients with differ-
ent levels of adherence. While education plays an important 
role on modifying beliefs, patients are likely to modify the 
recommended therapy based on how they feel or their level 
of dyspnea.
COPD patients with suboptimal adherence have insuf-
ﬁ  cient understanding about their illness and the options for 
managing their illness, show a low level of satisfaction with 
and faith in the treating physician, and rely more on natural 
remedies (George et al 2005). They also perceive the man-
agement of COPD as a mystery and show low conﬁ  dence in 
drug therapy (Turner et al 1995; Incalzi et al 2001; George 
et al 2005).
The degree of difﬁ  culty to handle some medications and 
patient satisfaction with the information shared by the doc-
tors is the more signiﬁ  cant patient experiences that correlate 
with adherence to therapy for COPD (George et al 2005). 
The level of patient satisfaction heavily depends on the 
adequacy of communication between clinician and patient as 
perceived by the patient. Although complexity of medication 
regimens, concerns about side effects, cost of treatment, and 
the number of regular medications in the regimen have been 
considered critical to adherence, these experiences have not 
been consistently correlated with poor adherence by all the 
studies (George et al 2005).
Since patients with COPD are often coached to increase 
their prescribed doses when exacerbations are identiﬁ  ed, the 
behavior of decreasing the doses when feeling well explains 
quite well the frequency of underuse in some patients with 
COPD. This change in frequency of therapy creates confusion 
about medications and results in sometimes not taking any 
actions when exacerbations arrive (George et al 2005).
A recent meta-analysis (DiMatteo et al 2007) suggested 
that the objective severity of patients’ disease conditions, 
and their awareness of this severity, can predict their 
adherence. Patients who are most severely ill with serious 
diseases may be at greatest risk for nonadherence to treat-
ment. Depression further complicates therapy adherence 
among COPD patients. Depressed medical patients are 
3 times more likely to be noncompliant with medication 
regimens, exercise, diet, health related behavior, vaccina-
tion, and appointments (DiMatteo et al 2007). Patients with 
Figure 2 Features of an inhaler considered “very important” by patients with COPD (Data from Moore and Stone 2004).
Overall ease of using
Being quick to when you need it
Knowing the dose has been taken
Easy to carry it in pocket/handbag
Pantients (%)
02 0 40 60 80 100
Ease of holding or gripping
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chronic illness are also likely to adhere to therapy if they 
trust the provider who prescribes the regimen, if there is 
evidence that the regimen is effective and does not cause 
distressing or frightening side effects that outweigh any 
therapeutic beneﬁ  ts, if the regimen does not signiﬁ  cantly 
interfere with important daily activities, and if it does 
not have a signiﬁ  cant impact on the individual’s sense of 
identity (Strauss and Glaser 1975).
Table 3 shows beliefs, experiences, and health behaviors 
identiﬁ  ed as strong predictors of low adherence to treatment 
in 276 patients with COPD. Each item is listed in order of 
statistical signiﬁ  cance compared with subjects with high 
adherence (George et al 2005).
Patient satisfaction, patient 
preferences, and quality of life
Although patient’s view of therapy is important as dis-
cussed above, relatively little has been investigated on 
the patient view of therapy involving monotherapy versus 
combination therapy and the use of a particular aerosol 
device. Most investigators assess the suitability of this 
form of therapy on response to lung function tests, reported 
improvements in exercise ability, and other indices of 
clinical efﬁ  cacy mentioned above. Evaluation of issues 
such as well-being and symptom control, self-conﬁ  dence, 
dependency, time and technical issues, as well as side 
effects and adherence provides a global assessment of 
quality of life. In a survey of 82 patients with chronic 
lung conditions on domiciliary nebulizer therapy, 98% 
of the patients receiving SVNs therapy reported favoring 
SVNs over pMDIs due to improved breathing, greater self-
conﬁ  dence, and less need to contact health care providers 
(Barta et al 2002).
The greatest change in quality of life have been reported 
when combination LABA – ICS is used in patients with 
COPD (mean reduction of 3.0 units over 3 years) compared 
with a placebo group (a mean score of 48.4 at baseline, with 
an increase of 0.2 unit in the placebo group) (Calverley et al 
2007). The combination BUD – FOR has a more signiﬁ  cant 
reduction in the St George Respiratory Questionnaire (SGRQ)  
than the FLU – SAL or placebo (D’Urzo et al 2001; Aaron 
et al 2007; Nannini et al 2007b).
Patients with COPD who are treated with an albuterol/
ipratropium combination via SVN have statistically signiﬁ  -
cant improvements from baseline in the SGRQ at 6 weeks. 
The concomitant use of SVN plus pMDI maintains signiﬁ  cant 
improvement in total questionnaire score and symptom 
sub-scores at week 12 (Tashkin et al 2007).
Self-reported adherence
Although several techniques are used to measure adherence, 
the most commonly used is based on self-reports, which 
tend to overestimate adherence (Farmer 1999). MARS is 
commonly used for self-reported adherence. A score of 25 
indicates perfect adherence (George et al 2005).
Fifty percent of patients with COPD do not take their 
medications as prescribed (James et al 1985). Patients on 
regimens of up to 4 times daily who take less than 70% of 
the dose prescribed, and those on regimens of 5 times daily 
or over who take less than 60% of the dose prescribed, are 
deﬁ  ned as poorly adherent (Moriskey et al 1986; Bosley et al 
1996). Underuse, especially during periods of respiratory 
distress, is more common than overuse (Chryssidis et al 
1981; James et al 1985; Dolce et al 1991).
While a qualitative study of compliance to medication and 
lifestyle modiﬁ  cation in patients with COPD found that all 
patients except one reported good adherence to medication 
(Jones et al 2004), the overall reported adherence to treatment 
in COPD ranges from 41.3% (Taylor et al 1984) to 57% 
(Dolce et al 1991; Bosley et al 1994). Factors such as fear of 
dyspnea and feelings of vulnerability appear to contribute to 
improvement in compliance. Ninety-three patients were asked 
how often they missed doses from their nebulizers and 66% 
Table 3 Beliefs, experiences, and health behaviors identiﬁ  ed 
predictors of low adherence to treatment in 276 patients with 
COPD.   The highlighted variables explained almost 20% variance 
in nonadherence in this study (George et al 2005)
Beliefs
I do not have sufﬁ  cient understanding about my illness
My doctors are not very knowledgeable
Natural remedies are safer than medicines
My doctors have limited management options to offer me
I do not have sufﬁ  cient understanding about the options for managing 
my illness
The management of my illness is a mystery for me
Experiences
It is unpleasant to use some of my medications
It is physically difﬁ  cult to handle some of my medications
I am not satisﬁ  ed with the information my doctors share with me
My doctors are not compassionate
My doctors don’t spend adequate time with me
Behaviors
I get confused about my medications
I vary my recommended management based on how I am feeling
I put up with my medical problems before taking any action
I make changes in the recommended management to suit my lifestyleInternational Journal of COPD 2008:3(3) 379
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stated that they never did (61% of the nonadherers and 72% of 
the adherers). Six percent reported missing doses only once a 
month, 10% admitted to missing doses once a week, and 7% 
(11% of the nonadherers and 3% of the adherers) stated that 
they missed a dose once a day (Bosley et al 1994). Eleven 
percent of both adherers and nonadherers stated that they used 
the nebulizer only when they felt they needed to. Forgetting 
or deciding not to dose has been reported as the most com-
mon cause of poor adherence (Figure 3) (Dolce et al 1991). 
Forgetting is reported by 51% of the patients, and 31% of the 
patients report consciously deciding not to dose.
Demographics
An evaluation of predictors of patient adherence to long-
term home nebulizer therapy in 985 patients with moderate 
to severe COPD enrolled in the Intermittent Positive Pres-
sure Breathing (IPPB) Trial revealed that 49.4% of patients 
were nonadherent (Turner et al 1995). Good adherence was 
predicted by white race, married status, abstinence from 
cigarettes and alcohol, serum theophylline level  9 pg/mL, 
more severe dyspnea, and reduced FEV1 (p   0.05). Subjects 
who were adherent to nebulizer therapy were older, better 
educated, had a stable lifestyle, were more likely to report 
that the therapy made them feel better, and were more likely 
to keep clinic appointments.
Reﬁ  ll adherence tends to be lower in younger patients, 
but lower in men than women (ratio of repeat prescriptions; 
40/60 men/women) (Rovelli et al 1989; Rand et al 1995; 
Leventhal and Crouch 1997). Men seem to have higher 
oversupplies (25%) than women (21%) and women slightly 
more undersupplies (22%) than men (20%) (Andersson et al 
2005). Older patients typically have more difﬁ  culty with the 
correct use of the inhaler than younger patients but there 
seems to be no difference in errors between men and women 
(van Beerendonk et al 1998).
A study on adherence to prescribed regimens of 74 
patients with COPD reported that almost 54% of the 
patients (men = 27, women = 15) stopped their medications 
periodically over the previous 3 months, 47% (men = 26, 
women = 11) noted forgetting doses over the previous 3 
months, and 44% (men = 23, women = 11) acknowledged 
being “careless” in taking their medications (Dolce et al 
1991). Thirty-nine patients (men = 25, women = 14) 
reported using more medication than was prescribed in 
times of distress. Thirty-eight percent of the men and 
12% of the women used their inhaled medications with 
unsatisfactory technique.
Independent variables that are signiﬁ  cantly associated 
with correct user of pMDI included sex and smoking status 
(Luk et al 2006). Men were more likely to use pMDI cor-
rectly: 77% of men used pMDI correctly, but only 33% of 
women used pMDI correctly. Non-smokers were more likely 
to have correct inhaler technique, whereas smokers were 
less likely. No signiﬁ  cant association was observed between 
Figure 3 Common causes of poor adherence. (Data from Dolce et al 1991). Solid bars indicate the top three reasons cited for missing medications.
Family problems interfered
Insufficient funds to purchase medications
Confused over schedule and decided not to dose
Socially inconvenient
Ran out of medicine
Side effects
Change in normal routine: unexpected
Change in normal routine: planned
Interrupted prior to doing ang forgot
Adsorbed in activity and forgot
Felt good and forgot to dose
Felt good and decided not to dose
05 1 0
Percent Reporting
15 20 25
Believed medication was not effective and did not...
Believed immune to medication;decided not to doseInternational Journal of COPD 2008:3(3) 380
Restrepo et al
age, drinking, education level or living condition and correct 
pMDI technique.
Impact of teaching
Although patients may read the instruction leaﬂ  et and receive 
face-to-face instruction, it is critical to evaluate whether or 
not patients are able to use the aerosol delivery device cor-
rectly. Patients’ interest in reading written medical informa-
tion such as how to use the inhaler may be inﬂ  uenced by 
several patient factors including disease state, health locus 
of control, coping style, health literacy levels, and occupa-
tion (Koo et al 2006) . Since non-adherent patients have a 
tendency to report more confusion about medications than 
the highly adherent group, health care providers may need 
to spend more time especially with the elderly and those 
patients with polypharmacy (George et al 2005).
Even immediately after face-to-face instruction patients 
make mistakes. In a study comparing the Diskus and the Tur-
buhaler DPIs, 8% of patients made mistakes using the Diskus 
DPI and 26% using the Turbuhaler DPI right after reading the 
instruction leaﬂ  ets (van der Palen et al 1998). Retention of 
instructions on appropriate use of the devices is progressively 
lost over time (van der Palen et al 1997). Inhalation technique 
was evaluated on average 6 months after they had received 
3 different forms of instruction. Ninety-seven percent of 
the patients with small-group instruction demonstrated a 
good inhalation technique in comparison to 75% after video 
instruction, and 76% after personal instruction.
Using “ideal” technique as an outcome, the relative risk 
of all steps correct in teaching intervention groups compared 
with non-intervention groups has been around 2.08 (95% CI 
1.59–2.78). The evidence shows that there is no difference 
between the pMDI and DPI. Any initial difference between 
the pMDI and DPI appears to be related partly to selection bias 
since appropriate inhaler technique achieved after a period of 
teaching has shown equivalent results for both pMDI and DPI 
(Brocklebank and Ram 2001). The inhaler technique improves 
by counseling and the percentage of subjects performing steps 
correctly may double (Luk et al 2006).
Evaluation of the proportion of patients with COPD who 
are compliant with ICS use after education in a 1-year follow 
up showed no signiﬁ  cant difference when compared with 
those who did not get the education (Gallefos et al 1999). 
However, the educated patients with COPD received less than 
half the amount of SABAs as rescue medications compared 
with the control group.
A sizeable number of primary care physicians treating 
patients with COPD are not aware of the GOLD guidelines 
and seem unclear about the role of inhaled medications at 
different stages of COPD (Foster et al 2007). Since primary 
care physicians provide care for a large percentage of patients 
with mild-to-moderate COPD, their diagnostic skills along 
with the knowledge and implementation of the guidelines is 
critical to the education, clinical outcome, and adherence to 
therapy of their patients with COPD.
Summary
By considering only adherence to medications and the impact 
of teaching, we are falling short of recognizing the critical 
role played by other forms of nonpharmacologic treatment 
such as smoking cessation, alternative medicine, diet, exer-
cise, and psychotherapy and their impact at different stages 
of COPD and/or in patients of different cultures. All aspects 
of therapy and the impact each one has on the currently 
reported poor adherence to COPD therapy need to be evalu-
ated. Adherence to therapy at different stages of COPD is 
important since the extent of impairment inﬂ  uences perceived 
symptoms, medication algorithms, ability to adhere with 
therapy and perceived beneﬁ  t of medication. This distinction 
could have signiﬁ  cant implications in important outcomes 
discussed earlier. However, we could not ﬁ  nd reports that 
measured the impact of speciﬁ  c stages of COPD on adher-
ence to medication.
Therapies for COPD can be effective and improve out-
comes only if well prescribed and if they are used by patients. 
The most common type of nonadherence to therapy is 
underuse. More than half of patients with COPD report miss-
ing or skipping doses of their medication (George et al 2005; 
Haupt et al 2008; Krigsman et al 2007a, b, c). Forgetting to 
dose is the most common situational factor that explains poor 
adherence (Dolce et al 1991; Bosley et al 1994). The deci-
sion not to dose due to feeling good is concerning. During 
respiratory distress, patients often report using more than 
the prescribed amount of medications (Bosley et al 1994; 
Dolce et al 1991).
Adherence also depends on clinical efﬁ  cacy of the pre-
scribed medications. In patients with COPD, a LABA – ICS 
combination produces a statistically signiﬁ  cant and clinically 
relevant beneﬁ  t without substantial differences between 
aerosol delivery systems. The superiority of combination 
inhalers should be viewed against the increased risk of 
side effects, particularly pneumonia (Calverley et al 2007). 
The class of medication appears to be uniformly associated 
with adherence. There is a noticeable pattern for patients to 
report better adherence with corticosteroids and antibiotics 
than with theophylline, inhaled beta agonists, and inhaled International Journal of COPD 2008:3(3) 381
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anticholinergic agents. Unfortunately, the underlying causes 
of these differences have not been determined. The com-
plexity of medication regimens frequently prescribed for 
patients with COPD adversely affect adherence to treatment 
(Krigsman et al 2007a).
When selecting an aerosol delivery device for patients 
with COPD, the following aspects should be considered to 
improve adherence to therapy: device – medication avail-
ability; clinical setting; patient age and the ability to use the 
selected device correctly; device use with multiple medica-
tions; cost and reimbursement; medication administration 
time; convenience in both outpatient and inpatient settings; 
and physician and patient preference. Almost all popular 
inhalers seem to be acceptable when overall preference is 
assessed, but most patients choose their devices based on 
ease of use in general and during an exacerbation, the feel 
of the device in the hand, ease of opening the cap, and the 
ability to take the medication quickly in case of an impend-
ing exacerbation (van der Palen et al 2007). Patients using 
combined SVN therapy morning and night with midday 
inhaler use seem to have the most statistically signiﬁ  cant 
improvements in quality of life. This concomitant regimen 
may provide the additional symptom relief offered by a SVN 
with the convenience of an inhaler when patients are away 
from home (Balzano et al 2000; Tashkin et al 2007). Since 
most patients consider the pMDI to be more acceptable and 
the SVN to be more effective, these preferences should be 
taken into consideration when prescribing a maintenance 
aerosol inhalation treatment.
There is signiﬁ  cant evidence showing that nearly 100% 
of patients with COPD make errors on the steps necessary 
to adequately use inhalers and many patients with COPD 
display a technique that possibly delivers an inadequate 
dose of medication (Hesselink et al 2001; Rau 2005; Luk 
et al 2006). However, the number of instructions needed to 
obtain a perfect inhalation technique and the type of instruc-
tion that sustains patient’s mastery over time has not been 
clearly deﬁ  ned. Regular instructions, supervision, and check 
up of inhalation technique are the responsibility of the treat-
ing physician. Under real-life conditions, inappropriate use 
of inhalers is common and strongly correlates with a lack of 
instruction by the caregiver (Sestini et al 2007). The beneﬁ  t 
of providing mere information and well-written instructions 
without “hands-on” demonstration has been thought as not 
providing information at all (Sestini et al 2007). Health 
professionals need to assess the utility of written medical 
information in the tailoring of patient education to meet 
patient needs.
Although insufﬁ  cient funds have been reported of limited 
importance as a factor limiting adherence to a medication 
regimen (Dolce et al 1991), pharmacoeconomics is con-
sidered a relevant issue in clinical practice (Roberts 2006). 
If reimbursement is considered, SVNs may be more cost 
effective and may explain why an increasing number of 
patients request a change to SVN (Rau 2005). Cost of the 
aerosol delivery device is at least as important as or perhaps 
more important than cost of the medication for adherence 
to therapy.
Patients’ acceptance and knowledge of the disease pro-
cess as well as the recommended treatment, faith in the treat-
ment, effective patient – clinician interaction are all critical 
for optimal medication adherence in patients with COPD. 
Psychological factors such as depression in patients with 
COPD have not been extensively studied. Depression may 
cause a patient to neglect themselves and their treatment and 
inﬂ  uence respiratory symptoms by being a cause of nonadher-
ence. It is very possible that the increased sense of impair-
ment in quality of life is associated with poor adherence 
to treatment (DiMatteo et al 2000, 2007). Although some 
studies have revealed an association between demographic 
variables such as gender, age, and race to adherence, studies 
with larger samples are needed (Andersson et al 2005; Luk 
et al 2006).
There is a need for further research to determine how, 
when, and where in the course of COPD patients need to be 
educated on all aspects of their disease to improve adherence 
to their prescribed therapeutic regimen. Physicians’ role on 
adherence should be thoroughly investigated to establish 
strategies that improve adherence since current evidence 
has been focused mostly on the patient level. The impact 
of poor implementation of existing guidelines for COPD 
by physicians on patients’ adherence to treatment has been 
poorly investigated. Only about 45% of primary care physi-
cians taking care of patients with COPD are aware of major 
COPD guidelines. However 75% of them do not use them 
to prescribe therapy for their patients with COPD (Foster 
et al 2007). The optimal use of recent advances in medicine 
depends heavily on developing effective communication 
between health care professionals and their patients (Mellins 
et al 1992). Strong education initiatives enable patients to 
respond effectively to the prescribed therapeutic regimens. 
A collaborative self-management approach recognizes the 
patient’s role in making his or her own health decisions 
and the physician’s role as an educator and facilitator of 
the patient’s health decisions (Barry 2003). Health care 
practitioners should recognize the complexity of prescribed International Journal of COPD 2008:3(3) 382
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treatments and routinely utilize strategies to promote patient 
adherence.
Improving efforts by the physicians to increase education 
about the illness and the treatment options along with the 
inclusion of psychological treatments in management plans 
is critical to improving adherence to therapy in patients with 
COPD who ﬁ  nd every day a challenge to adhere to their 
therapeutic regimen.
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